HLS Therapeutics Community

TSX:HLS Community

1 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

HLS Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

Key Takeaways Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue. Strategic cost reductions and expansion through partnerships aim to support growth, while share buybacks enhance earnings per share.

CA$6.11

FV

30.7% undervalued

5.16%

Revenue growth p.a.

0

0

0

2 days ago